KRAS and neoplasm: Second, LHR showed no statistical difference when stratified by demography characteristics (age and sex), primary tumor characteristics (tumor location, type or differentiation of pathology, T and N stage, and KRAS mutation), metastatic site characteristics (presence of extrahepatic disease, number of CRLMs, and Fong score), or systematic inflammation biomarkers (LDH levels, LNR, LMR, and lymphocyte-to-platelet ratio; p-values >0.05 for all) [electronic supplementary Table S1].